← Back

Veracyte Inc

Veracyte, Inc. is a diagnostics company operating in the United States and internationally. It offers genomic tests including Afirma for thyroid nodules, Decipher Prostate and Decipher Bladder for prostate and bladder cancer, Prosigna for breast cancer, and Percepta Nasal Swab for lung cancer. The company also provides nCounter analysis system services. Formerly known as Calderome, Inc., it changed its name to Veracyte, Inc. in March 2008, was incorporated in 2006, and is headquartered in South San Francisco, California.

Price · split & dividend adjusted
News & notes moving VCYT
VCYT▼impact 4

Apple and Amazon lead midday movers after earnings reports

Several stocks made big midday moves following earnings reports and other developments. IES Holdings surged over 30% after beating quarterly expectations and approving a two-for-one stock split, while GoDaddy tumbled 20% on disappointing guidance and a cash flow miss. Newell Brands rose 11% after lifting its full-year earnings outlook above consensus, and SPX Technologies rallied 14% on strong results and raised guidance. Veracyte fell 24% despite beating estimates and raising revenue guidance, and Replimune Group soared over 94% after an FDA panel backed its skin cancer drug trial. Jersey Mike's gained 6% on its second day of trading after a weak debut. Chevron added 1.6% on better-than-expected earnings, while ExxonMobil slipped 2% on a profit miss. Moderna dipped 1% despite a top- and bottom-line beat. Amazon jumped 15% on strong revenue and cloud growth, but Apple dropped more than 9% even with higher iPhone sales. Coinbase slid over 12% after a wider-than-expected loss, Reddit sank 22% on search traffic concerns, and Novo Nordisk fell 9% after a drug trial failed to meet its main goal.
AAPL ▼AMZN ▲COIN ▼CVX ▲GDDY ▼IESC ▲+8
CNBC·49dRead more →
Biotech & Genomic Medicine▲

Veracyte Rises on Upward Guidance Revision and Earnings Beat

Veracyte shares advanced sharply after the genomic diagnostics company reported a strong earnings beat and raised its full-year guidance, according to the Meridian Small Cap Growth Fund's second-quarter 2026 investor letter. The fund, managed by ArrowMark Partners, highlighted that Veracyte's performance was underpinned by continued double-digit volume growth in its Decipher prostate cancer test and improved Afirma thyroid test results following a workflow upgrade. Two upcoming launches—Prosigna in breast cancer and the TrueMRD platform in bladder cancer—along with a steady cadence of clinical data, reinforced confidence in a multi-year growth runway. Veracyte closed at $55.71 per share on July 29, 2026, with a market capitalization of $4.44 billion, and its shares gained 136.96% over the past 52 weeks.
VCYT ▲
Biotech & Genomic Medicine ▲
Insider Monkey·50dRead more →
© 2026 MarketDXAsset